Liver Disorders
US Hepatology Partner
EU Hepatology Partner
Global Hepatology Partner
An Introduction to Liver Disorders
Hepatology covers hepatitis, hepatocellular carcinoma (HCC), nonalcoholic fatty liver disease (NAFLD), cirrhosis and rarer conditions such as autoimmune and cholestatic liver diseases. Despite numerous advances, liver-related mortality has remained stable for over 30 years. The World Health Organization has set targets for hepatitis C elimination by 2030. Immunotherapy and combination therapies have greatly increased the efficacy of the treatment of hepatocellular carcinoma (HCC). However, as a result of the increasing prevalence of obesity, NAFLD is reaching epidemic proportions and poses a major challenge to global public health. There is an urgent need for long-term management strategies and pharmacological interventions for NAFLD.
Our supporting partners do not constitute an endorsement of the content on this page.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Findings from the Spring Study – CM-101 for Primary Sclerosing Cholangitis: Paul Pockros, DDW 2025
In the interview, Dr Paul Pockros discusses his presentation from DDW 2025 on the SPRING study (NCT04595825), which evaluated CM-101, a novel anti-CCL24 monoclonal antibody, in adults with primary sclerosing cholangitis (PSC). With no FDA-approved treatments for PSC, CM-101 showed promising safety, tolerability, and biomarker improvements over 48 weeks, supporting advancement to phase 3 trials.
The EASL 2024 meeting offered a great opportunity for hepatologists from around the world to discuss the latest data and tackle challenges in liver disease. Metabolic dysfunction-associated steatohepatitis (MASH) was a hot topic, with several exciting studies making waves. This article ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
